164results about How to "Inhibit growth" patented technology

A biofilm penetrating composition for coating medical devices for substantially preventing the growth or proliferation of biofilm embedded microorganisms on at least one surface of the medical device is disclosed. A biofilm penetrating composition solution for cleaning medical devices which is capable of substantially removing all of the biofilm embedded microorganisms from at least one surface of medical devices is also disclosed. The biofilm penetrating composition coating and solution include a biofilm penetrating agent and may also include a base material. Medical devices coated with the biofilm penetrating composition and methods for coating medical devices and methods for removing biofilm embedded microorganisms from at least one surface of the medical devices are also disclosed.

In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.

The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). One chain of a heterodimer comprises a binding domain that specifically binds a target (e.g., a receptor). In addition, both chains of a heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in reducing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.

The present invention generally relates to articles of manufacture, such as medical devices, having a non-fouling surface comprising a grafted polymer material. The surface resists the adhesion of biological material.

Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of such cancers. Additionally, the invention provides a method of increasing the cytotoxicity of forms of Pseudomonas exotoxin A (“PE”) with the mutation of a single amino acid, as well as compositions of such mutated PEs, nucleic acids encoding them, and methods for using the mutated PEs.

All or a portion of a surface of an implantable sensor is covered with a biocompatible coating formed at least partially of a biomaterial matrix having properties that promote a substantially even growth of tissue cells over the surface of the coating. Additional materials, such as growth factors, agents that recruit endogenous stem cells, and cell adhesion motif arginine, glycine, aspartic acid may be included in the coating. Autologous cells may be added to the coating prior to implantation. The sensor surface may also be textured, by etching or abrading, in order to promote even tissue growth. Alternatively, the sensor surface may be covered with a coating having properties that inhibit the growth of tissue. These coatings may include a biomaterial, a biomaterial matrix having a drug, such as a sirolimus or a steroid, an active component, or a self assembled monolayer.

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.

A preservative and flavoring system for tea based beverages. The system contains a tea extract, an antimicrobially active amount of cinnamic acid or an acidic derivative thereof and an acidulant in an amount that maintains the pH of the beverage below pH 4.5. The system preferably includes an additional preservative such as a weak acid preservative. It can be used to prepare an ambient-stable tea based beverage and is suitable for cold filling.

The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.

A synergistic anti-bacterial composition, including: (a) an extract of botanical materials, the botanical materials including material from Plantago species, Hypericum species, Echinacea species and Propolis; and (b) oil of cinnamon.

Methods of using colony stimulating factor receptor (CSF1R) extracellular domain (ECD) fusion molecules to treat treating osteolytic bone loss, cancer metastasis, cancer metastasis-induced osteolytic bone loss, and tumor growth are provided. CSF1R ECD fusion molecules, polynucleotides encoding CSF1R ECD fusion molecules, and methods of making CSF1R ECD fusion molecules are also provided.

Methods of therapy for treating a subject for chronic lymphocytic leukemia are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CN40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing chronic lymphocytic leukemia cells.

The present invention includes compositions for preventing growth and proliferation of biofilm embedded microorganisms comprising: (a) a cationic polypeptide and (b) a bis-guanide or a salt thereof. The invention further provides methods for preparing objects with such compositions, and objects and consumables (such as household cleaners) comprising such compositions.

The present invention relates to a novel phage, which is newly isolated and identified, a composition for inhibiting growth of bacteria or killing thereof comprising the same as an active ingredient, and the present invention can be diversely used as a composition for preventing or treating bacterial infectious diseases, a composition for treating ballast water, an antibiotic, an antiseptic, a feed additive and the like.

Nucleotide sequences are disclosed that may be used to impart herbicide resistance to green plants. The sources of novel resistance were originally isolated in mutant rice plants. The sequences impart pre-emergence resistance, post-emergence resistance, or both pre-emergence resistance and post-emergence resistance to multiple herbicides. To date, resistance has been demonstrated against at least the following herbicides: imazethapyr, imazapic, imazapyr, imazamox, sulfometuron methyl, imazaquin, chlorimuron ethyl, metsulfuron methyl, rimsulfuron, thifensulfuron methyl, pyrithiobac sodium, tribenuron methyl, and nicosulfuron. Green plants transformed with these sequences are resistant to these herbicides and to derivatives of these herbicides, and to at least some of the other herbicides that normally inhibit acetohydroxyacid synthase (AHAS), particularly imidazolinone and sulfonylurea herbicides.

This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.

The invention discloses a composite carbon cathode material for a lithium ion battery and a preparation method thereof, and relates to a cathode material for a lithium ion battery. The invention provides the composite carbon cathode material for the lithium ion battery and the preparation method thereof, wherein the composite carbon cathode material can reduce the influence of a solid electrolyte interface (SEI) film on the cyclical stability of the cathode material, partially prevent anode dissolved metal ions from being deposited on the surface of the cathode material to affect the cyclical performance of the cathode material and still provide high specific energy under the condition of high charging current. The composite carbon cathode material is provided with a nuclear shell layer structure of at least three layers, wherein the outer layer is a metal layer, an alloy layer or a carbon layer; the middle layer is a lithiated metal oxide layer or a metal oxide layer; and the inner layer is a carbon material layer. The preparation method comprises the following steps of: mixing and then drying a raw material for preparing a metal oxide and a carbon material; heating and sintering the dried raw materials under the protection of atmosphere to obtain a composite material of the lithiated metal oxide or metal oxide layer with nuclear shell structure and the carbon material; and plating a metal, alloy or carbon conductive layer with reversible mechanical ductility on the surface of the composite material to obtain a product.

Food products fortified by purified PQQ and methods of application and production are disclosed. A method of preserving a food product comprising admixing an effective amount of purified PQQ or a compound containing purified PQQ derivatives with a foodstuff to provide an inhibiting means to microorganism growth in the food product.

The present invention provides a process for the production of a frozen food product comprising the step of contacting a food intermediate with an emulsifier system, wherein the emulsifier system consists essentially of compounds of formula I:

wherein R₁ is a hydrocarbon group; and optionally mono-diglycerides and/or unsaturated lactylated mono-diglycerides.

The present invention relates to B7-H4-specific compositions and methods of use thereof.

The present invention provides a laspartomycin core peptide, a laspartomycin core peptide derivative, a antimicrobial laspartomycin derivative, a method for making laspartomycin core peptides, methods for making laspartomycin core peptide derivatives, methods for making antimicrobial laspartomycin derivatives, pharmaceutical compositions of antimicrobial laspartomycin derivatives, methods of inhibiting microbial growth and methods for treating and/or preventing microbial infections in a subject.

The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of an immune response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent, visible, delayed inflammatory immune reaction at the successive site or sites of administration.

The invention relates to a preparation method of a high-temperature-resisting aerogel material. The method comprises the following steps: (1) preparing sol; (2) carrying out a nano-crystal assemblingprocess to prepare aerogel wet gel which takes an oxide nano-crystal as a framework; (3) preparing an aerogel material; (4) carrying out a heat treatment process to prepare the high-temperature-resisting aerogel material. According to the preparation method provided by the invention, a nano-crystal assembling technology and heat treatment are combined to prepare the high-temperature-resisting aerogel material with a microcosmic core-shell structure; the core-shell structure forms a network framework under high temprature so that the growth of the oxide nano-crystal is inhibited and the shrinkage problem caused by the fact that the structure of oxide aerogel collapses in a high-temperature utilization process is effectively solved. The aerogel material prepared by the preparation method hasa good high-temperature-resisting property; the heat-resisting temperature is 1000 DEG C or more and the high-temperature-resisting aerogel material even can bear the high temperature of 1300 DEG C or more.

The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.

The invention discloses a method for preparing a hollow porous Na2MnPO4F/C nanometer fiber positive electrode material. The method comprises the following steps of dissolving a sodium source, a manganese source, a phosphoric acid source, a fluorine source, a chelating agent and a macromolecular polymer in a solvent, and performing stirring to form a spinning solution A; selecting oil as a spinning liquid B, performing coaxial electrostatic spinning by taking the spinning liquid B as an internal shaft and the spinning liquid A as an external shaft to obtain a coaxial nanometer fiber; placing the coaxial nanometer fiber in an extraction agent to remove an oil phase, and obtaining a hollow nanometer fiber precursor after drying; and performing thermal processing in a non-oxidization atmosphere, and obtaining the Na2MnPO4F/C positive electrode material after cooling. The Na2MnPO4F/C hollow porous nanometer fiber is prepared by an electrostatic spinning method, the electron conductivity and the ion conductivity of the positive electrode material are remarkably improved, so that the rate performance of the battery is improved, and the cycle property of the battery is favorably improved.

The invention relates to the fields of halogen free flame retardant materials and preparation technology thereof, in particular to an attapulgite/hydrotalcite compound flame retardant material and preparation method thereof. The attapulgite/hydrotalcite compound flame retardant material has hydrotalcite and attapulgite; the mass ratio between the hydrotalcite and the attapulgite is 0.4-2.5 to 1. The attapulgite is used as a substrate to prepare the attapulgite/hydrotalcite compound flame retardant material in situ as the surface of the attapulgite is electronegative and can absorb electropositive nano hydrotalcite in situ. The attapulgite and the hydrotalcite are used for simultaneously retarding flame and inhibiting smoke. The attapulgite/hydrotalcite compound flame retardant material has the functions of retarding flame and inhibiting smoke, so that the technical problem of undesirable smoke inhibiting effect of the current flame retardant material is solved.

Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.

The present invention provides a novel amide derivative and a pharmaceutically acceptable salt thereof which selectively and effectively inhibits the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor and also prevents the development of drug resistance caused by the mutation of EGFR tyrosine kinase, and a pharmaceutical composition comprising same as an active ingredient.

The present invention concerns a (4(2′-aminoethyl)amino-1,8-dimethylimididazo(1,2-a)quinoxaline)-4,5-dihydro-1,8-dimethylimidazo(1,2-a)quinoxalin-4-one-2-carboxylic acid (BMS-345541) or an analog thereof for the treatment of melanoma cancer. This compound inhibits NFκB activity and expression, and induces apoptosis in melanoma cancer cells. The present invention also provides a method for assaying for the inhibition of melanoma cancer cell growth.

The present invention provides novel compounds described herein, such as of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.